Company officials say its proprietary Tumor Treating Fields technology, marketed under the product name Optune, are a new tool in the war against cancer. Currently, the company has FDA approval for Glioblastoma, the deadliest form of brain cancer.
The results thus far have been impressive for Novocure. In December, data from the company’s pivotal phase 3 trial of its Optune device, published in the Journal of the American Medical Association, showed that Optune along with temozolomide chemotherapy significantly extended progression-free survival and overall survival compared to temozolomide alone in treating newly diagnosed glioblastoma.
MassDevice publisher Brian Johnson recently caught up with Bill Doyle, chairman, NovoCure to discuss the technology, the company’s origins and how its current concentration on glioblastoma is just the beginning for the company.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.